Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A Year in Review and a Look to the Future: BTKi in CLL and MCL

27:33
 
Share
 

Manage episode 384873627 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:

  • SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
  • TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
  • ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
  • BRUIN: Pirtobrutinib for Previously Treated MCL
  • GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
  • FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
  • ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
  • ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
  • BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters:

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri

  continue reading

191 episodes

Artwork
iconShare
 
Manage episode 384873627 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:

  • SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
  • TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
  • ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
  • BRUIN: Pirtobrutinib for Previously Treated MCL
  • GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
  • FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
  • ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
  • ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
  • BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters:

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri

  continue reading

191 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play